(6S)-6-[2-Chloro-3[(2-cyclopropylpyrimidin-5-yl)amino)-phenyl]-2-imino-6-methyl-3-[(2S,4S)-2-methyltetrahydropyran-4-yl]hexahydropyrimidin-4-one

ID: ALA5204196

Chembl Id: CHEMBL5204196

PubChem CID: 165412421

Max Phase: Preclinical

Molecular Formula: C24H29ClN6O2

Molecular Weight: 468.99

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H]1C[C@@H](N2C(=N)N[C@](C)(c3cccc(Nc4cnc(C5CC5)nc4)c3Cl)CC2=O)CCO1

Standard InChI:  InChI=1S/C24H29ClN6O2/c1-14-10-17(8-9-33-14)31-20(32)11-24(2,30-23(31)26)18-4-3-5-19(21(18)25)29-16-12-27-22(28-13-16)15-6-7-15/h3-5,12-15,17,29H,6-11H2,1-2H3,(H2,26,30)/t14-,17-,24-/m0/s1

Standard InChI Key:  RUZADINCVKIRSK-NPALWHDTSA-N

Alternative Forms

  1. Parent:

    ALA5204196

    ---

Associated Targets(Human)

CTSD Tchem Cathepsin D (3201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
REN Tclin Renin (5251 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

PMX Plasmepsin X (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 468.99Molecular Weight (Monoisotopic): 468.2041AlogP: 4.29#Rotatable Bonds: 5
Polar Surface Area: 103.23Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 5.17CX LogP: 2.90CX LogD: 2.90
Aromatic Rings: 2Heavy Atoms: 33QED Weighted: 0.60Np Likeness Score: -0.45

References

1. Lowe MA, Cardenas A, Valentin JP, Zhu Z, Abendroth J, Castro JL, Class R, Delaunois A, Fleurance R, Gerets H, Gryshkova V, King L, Lorimer DD, MacCoss M, Rowley JH, Rosseels ML, Royer L, Taylor RD, Wong M, Zaccheo O, Chavan VP, Ghule GA, Tapkir BK, Burrows JN, Duffey M, Rottmann M, Wittlin S, Angulo-Barturen I, Jiménez-Díaz MB, Striepen J, Fairhurst KJ, Yeo T, Fidock DA, Cowman AF, Favuzza P, Crespo-Fernandez B, Gamo FJ, Goldberg DE, Soldati-Favre D, Laleu B, de Haro T..  (2022)  Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362.,  65  (20.0): [PMID:36216349] [10.1021/acs.jmedchem.2c01336]

Source